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a b s t r a c t
Epithelial ovarian cancer is characterized by a high mortality rate and is in need for novel therapeutic
avenues to improve patient outcome. The tumor’s extracellular matrix (‘‘stroma”) offers new possibilities
for targeted drug-delivery. Recently we identified highly sulfated chondroitin sulfate (CS-E) as a compo-
nent abundantly present in the ovarian cancer extracellular matrix, and as a novel target for anti-cancer
therapy. Here, we report on the functionalization of drug-loaded lyophilisomes (albumin-based biocap-
sules) to specifically target the stroma of ovarian carcinomas with the potential to eliminate cancer cells.
To achieve specific targeting, we conjugated single chain antibodies reactive with CS-E to lyophilisomes
using a two-step approach comprising sortase-mediated ligation and bioorthogonal click chemistry.
Antibody-functionalized lyophilisomes specifically targeted the ovarian cancer stroma through CS-E. In
a CS-E rich micro-environment in vitro lyophilisomes induced cell death by extracellular release of dox-
orubicin which localized to the nucleus. Immunohistochemistry identified CS-E rich stroma in a variety of
solid tumors other than ovarian cancer, including breast, lung and colon cancer indicating the potential
versatility of matrix therapy and the use of highly sulfated chondroitin sulfates in cancer stroma as a
micro-environmental hook for targeted drug delivery.
 2016 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Epithelial ovarian cancer is the fifth leading cause of cancer-
related death in women worldwide [1]. Most patients are diag-
nosed with an advanced stage of disease (Fédération Internationale
de Gynécologie et d’Obstétrique (FIGO) stage III–IV) and suffer
from extensive abdominal metastases [2,3]. Aggressive surgical
cytoreduction and chemotherapy are used as primary treatment,
but nevertheless up to 70% of these patients will develop recurrent
disease and eventually succumb. Long term survival is poor with a
5-year survival of less than 35% [2,3]. Overall survival statistics
have not significantly improved over the last decades and new ave-
nues for better treatment are clearly warranted [4].
Conventional chemotherapeutics affect proliferating cancer
cells as well as normal cells, resulting in systemic adverse events
that greatly affect quality of life. As a consequence, the dose
administered has to be limited resulting in a suboptimal treatment
that negatively affects prognosis of cancer patients. The use of drug
delivery systems may be helpful to overcome these problems by
improving biodistribution, resulting in high local drug concentra-
tions at the tumor site while minimizing exposure to healthy cells
[5]. Beneficial effects of drug delivery systems such as liposomal
doxorubicin (Caelyx/Doxil) and albumin bound paclitaxel (nab-
paclitaxel), have been reported in several (pre)-clinical studies
[6–9]. Previously we described a novel class of drug delivery vehi-
cles, lyophilisomes, which are spherical nano- to microsized bio-
capsules that can be prepared from various proteins (e.g.
albumin, collagen, and elastin) [10,11]. Albumin-based lyophili-
somes can be efficiently loaded with doxorubicin and are able to
eliminate ovarian cancer cells in vitro [10]. In addition, the albumin
wall of lyophilisomes offers opportunities for functional modifica-
tion, e.g. by the incorporation or conjugation of components in
and/or on the wall. Antibody-conjugated lyophilisomes have been
shown to specifically bind to cancer cells expressing the corre-
sponding antigen, thus enabling active cancer-targeting [12].
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Although it is hypothesized that active targeting of cancer cells
by drug delivery systems using specific antibodies or ligands has
the potential to broaden the therapeutic index of anti-cancer
drugs, the favorable effect of tumor-cell targeting over non-
targeting systems was reported to be disappointing [5,6,13]. As
most of these studies have focused on targeting cancer cells, other
approaches such as targeting the cancer extracellular matrix (ECM)
may offer valuable alternatives [14].
The ECM represents a network of proteins and proteoglycans
that is abundantly remodeled during cancer development and
actively contributes to cancer progression [15,16]. A large amount
of intratumoral matrix correlates with poor prognosis in cancer,
including ovarian cancer [17]. Major components of the ECM are
collagen, laminin and proteoglycans. Proteoglycans function to a
large extent through their glycosaminoglycan side chains; linear
negatively charged polysaccharides built from repeating disaccha-
rides [18]. Highly 4,6-sulfated chondroitin sulfate (CS-E), a specific
class of glycosaminoglycans, is found to be abundantly expressed
in the ovarian cancer stroma while being absent or present in only
very small amounts in healthy stroma, thus representing an attrac-
tive target for anti-cancer therapy [19,20]. Interestingly, the
amount of these targets expressed in the stroma is relatively high
when compared to targets expressed at the cancer cell surface.
In this study, we present an innovative concept of an anti-
cancer strategy aiming at forming a depot of chemotherapeutic-
loaded lyophilisomes in the ovarian cancer ECM. Targeting the can-
cer ECM rather than cancer cells might be helpful to overcome hur-
dles observed in cell-targeting therapies as the cancer ECM is a
relatively stable structure, unlike cancer cells that are characteris-
tically genetically instable [21]. Due to intratumoral heterogeneity,
cell-targeting therapies may only affect subpopulations of cancer
cells, and leave other cancer cells and cancer-promoting cells
(e.g. cancer-associated fibroblasts, endothelial cells, and macro-
phages) unaffected [22]. Release of chemotherapeutics from a
depot of drug-loaded lyophilisomes in the cancer ECM may affect
all cells in its vicinity including cancer cells, cancer stem cells
and cancer-associated stromal cells. Collagens have been used as
micro-environmental anchors for targeted anti-cancer therapy
[23,24], but collagen is also abundantly present in normal tissues.
Therefore, in this study we focus on CS-E as a much more cancer-
specific molecular target. We describe the construction and evalu-
ation of a lyophilisome-based drug delivery system specifically tar-
geting highly sulfated CS-E in the ovarian cancer stroma.
2. Materials and methods
2.1. Patient material
Study approval was given by the Regional Committee for Med-
ical Research Ethics and performed according to the Code for
Proper Secondary Use of Human Tissue (Dutch Federation of
Biomedical Scientific Societies, www.federa.org). Cryosections
(5 lm) of advanced stage high grade serous ovarian cancer were
used for immunofluorescent analysis of antibody-functionalized
lyophilisome specificity. Paraffin embedded sections (4 lm) of
lung, cervical, breast, renal cell, endometrial, and colon cancer
were used for immunohistochemical analysis of CS-E expression.
2.2. Production of antibody-functionalized lyophilisomes
2.2.1. Modification of GD3G7 antibodies for sortase-mediated
conjugation
The single chain antibody GD3G7 was previously selected
against embryonic glycosaminoglycans and showed specificity for
CS-E [19]. For site-selective conjugation of GD3G7 at the carboxy
terminus, leaving the antigen-binding parts of this antibody intact,
the LPETG sortase A-recognition motif was introduced. To this end
the GD3G7 reading frame was cloned in plasmid pHENIX-LPETG-
His-VSV to yield pHENIX-GD3G7-LPETG-His-VSV. Expression of
the fusion protein in E. coli strain ER2566 was induced with
isopropyl b-D-thiogalactoside (IPTG) as described previously
[25]. GD3G7-LPETG-His-VSV was released from the periplasmic
space via osmotic lysis using 200 mM Tris-HCl, pH 8.0, 0.5 mM
ethylenediaminetetraacetic acid (EDTA), 20% (w/v) sucrose con-
taining protease inhibitors. Purification by nickel-NTA affinity
chromatography was performed as described (NTA-Ni Sepharose,
IBA Life sciences) [26].
2.2.2. Introduction of DBCO functionality to GD3G7 by sortagging
pGBMCS-SortA, a gift from Dr. Fuyuhiko Inagaki [27] was trans-
fected into E. coli ER2566 for standard protein expression. Bacterial
expression was performed as described and IPTG-induced cells
were lysed by sonication at 4 C using a Bandalin Sonopuls
HD2070 sonicator. His-tagged sortase was purified with NTA-Ni
Sepharose as described above.
To equip the GD3G7 antibody with a bio-orthogonal chemical
click handle (Fig. 1), 16 lM GD3G7-LPETG-His-VSV was incubated
overnight at room temperature with 4 mM amino-PEG4-DBCO
(Click Chemistry Tools, Scottsdale, USA) in the presence of
40 lM sortase A in 50 mM Tris, 150 mM NaCl, 10 mM CaCl2, pH
7.5. Reaction product was cleared from unreacted GD3G7-
LPETG-His-VSV, cleaved G-His-VSV tags and sortase A by
depletion on nickel-NTA beads. Free amino-PEG4-DBCO was
removed by filtration in PBS over a 10 kDa centrifugal filter
device (Amicon Ultra-4, Merck Millipore) using standard
protocols. Routinely, filters were washed five times to obtain
highly purified product.
The sortase mediated reaction was evaluated by applying
bioorthogonal click chemistry between DBCO and azide. The sor-
tagged product was incubated with azido-cyanine-7.5 (Lumiprobe
GmbH, Hannover, Germany) for 1 h at 4 C, followed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
using 10% gels and gel imaging at 800 nm (Odyssey CLx imaging
system). Thereafter, gels were stained for presence of proteins with
0.1% (w/v) Coomassie Brilliant Blue R-250 solution (MP Biomedi-
cals, Santa Anna, CA) in 50% (v/v) methanol and 10% (v/v) acetic
acid in water.
2.2.3. Preparation of lyophilisomes and introduction of azide
functionality
Lyophilisomes were prepared from bovine serum albumin (BSA;
PAA Laboratories, Linz, Austria) as described previously [10].
Briefly, droplets of 20 ll 2.5 mg/ml BSA (containing 10% FITC-
labeled BSA (Sigma-Aldrich, St. Louis, MO, USA)) in 0.01 M acetic
acid were snap frozen in liquid nitrogen. Capsules were formed
using an annealing and lyophilization regimen [11]. Large struc-
tures were removed by centrifugation (60g).
Lyophilisomes were prepared for click chemistry by introducing
azide groups to the surface of lyophilisomes. Lyophilisomes were
suspended in PBS containing 0.1% tween20 (v/v) (PBST; pH 8.0),
sonicated (Cycle 0.5; Amplitude 20; 10 cycles) with a Sartorius lab-
sonic P sonicator (Göttingen, Germany), mixed with 100 times
molar excess NHS-PEG4-azide (Jena Bioscience, Jena, Germany)
and incubated under rotation at room temperature overnight.
Next, lyophilisomes were washed three times with PBST and cen-
trifuged at 17,000g for 5 min to remove free NHS-PEG4-azide,
and stored in PBST at 4 C.
Modification of lyophilisomes with PEG4-azide was analyzed
using flow cytometry. Lyophilisomes (2.5 lg) with or without
PEG4-azide were incubated with 1 lg/ml DBCO-IR dye 680RD (LI-
COR Biotechnology, Bad Homburg, Germany), which binds only
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azido modified lyophilisomes, in PBST under rotation at room
temperature for 1 h. Control samples were incubated in PBST only.
Lyophilisomes were three times washed with PBST and centrifuged
at 17,000g for 5 min, re-suspended in PBST and analyzed for their
680RD signal with a BD FACSCalibur flow cytometer (BD Bio-
sciences, Breda, the Netherlands). Data were analyzed using FlowJo
software (Version 10, Treestar, Ashland, OR).
2.2.4. Loading of lyophilisomes with doxorubicin
Loading of lyophilisomes with doxorubicin was performed as
described previously [10]. In short, 200 lg of lyophilisomes with
or without GD3G7 antibody were washed twice with 10 mM 4-(2
-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer
(pH 7.4; Promega, Madison, WI, USA) and centrifugated at
17,000g for 5 min at 4 C. Next, lyophilisomes were incubated
overnight with 500 ll 0.5 mg/ml doxorubicin (Accord Healthcare,
the Netherlands) in 10 mM HEPES buffer v/v at room temperature.
Non-entrapped doxorubicin was removed by centrifuging at
17,000g, 5 min, 4 C and collecting the supernatant. Subsequently,
the lyophilisomes were washed three times with 10 mM HEPES
buffer (17,000g, 5 min, 4 C) and the supernatants were collected.
The doxorubicin concentration in 10 mM HEPES buffer of the three
collected supernatants was quantified spectrophotometrically at
490 nm (Synergy BioTek 2 Plate reader, BioTek, Winooski, VT,
USA). The entrapment efficiency was calculated using the follow-
ing formula:
Entrapment efficiency ð%Þ ¼ ½doxorubicintotal ½doxorubicinfree½doxorubicintotal
 100
Fig. 1. Construction of cancer targeting lyophilisomes. Schematic overview of the conjugation between albumin-based lyophilisomes and GD3G7 antibodies reactive with CS-
E, by applying a two-step approach comprising sortase mediated ligation and click chemistry. (A) LPETG-His-VSV tagged single chain GD3G7 antibodies were modified for
click chemistry by introducing amino-PEG4-DBCO through a reaction mediated by Sortase A. (B) Lyophilisomes were functionalized for click chemistry by conjugating PEG4-
azide to the primary amine groups of lyophilisomes mediated by N-hydroxysuccinimide (NHS). (C) Antibody-functionalized lyophilisomes were generated by a click reaction
between azido-conjugated lyophilisomes and GD3G7-PEG4-DBCO antibodies. Abbreviations: CS-E, chondroitin sulfate E; DBCO, dibenzylcyclooctyne; VL, light chain variable
domain; VH, heavy chain variable domain; SrtA, Sortase A.
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2.2.5. Antibody functionalization of lyophilisomes
In order to achieve specific targeting of lyophilisomes to CS-E,
GD3G7 antibodies were conjugated to lyophilisomes through
bioorthogonal click chemistry. A 1.25 molar excess GD3G7-
LPET-PEG-DBCO was reacted to azido-conjugated lyophilisomes
in PBST via the scheme depicted in Fig. 1C. Reaction was allowed
to proceed overnight at room temperature. In a control reaction,
azide-conjugated lyophilisomes were incubated with unmodified
GD3G7 antibodies. Free antibodies were removed through three
washing steps with PBST by centrifugation at 17,000g for 5 min.
Conjugation was evaluated using horseradish peroxidase-
conjugated Protein A that binds to the VH3 domain of the antibody
[19]. Antibody-functionalized lyophilisomes and non-
functionalized lyophilisomes (2.5 lg) were incubated with
0.1 lg/ml peroxidase-Protein A (Merck Millipore, Darmstadt, Ger-
many) in PBST for 1 h under rotation at room temperature. After-
wards, lyophilisomes were washed three times with PBST,
centrifuged at 17,000g for 5 min and peroxidase activity in the pel-
lets was measured by reaction in 0.0243 M citric acid, 0.0514 M
K2HPO3, 0.012% H2O2 (v/v) and 0.04% ortho-phenylenediamine
(w/v). After 30 min at room temperature, 12.5% H2SO4 (v/v) was
added to stop the reaction. Subsequently, lyophilisomes were cen-
trifuged and the absorbance of the supernatant was measured at
492 nm using a Synergy BioTek 2 Plate reader (BioTek, Winooski,
VT, USA).
2.3. Evaluation of the targeting potential of antibody functionalized
lyophilisomes
2.3.1. Binding to ovarian cancer stroma
Human ovarian cancer cryosections (5 lm) were pre-treated
with 2 mMMgAc2 in 25 mM TrisHCl buffer (pH 8.0) with and with-
out the chondroitin sulfate digesting enzyme chondroitinase-AC
(30 mU/ml, 1 h, 37 C). After blocking with 2% BSA in PBS (w/v),
sections were incubated with either antibody-functionalized
lyophilisomes or non-functionalized lyophilisomes (0.1 mg/ml in
2% BSA in PBS) for 1 h. Nuclei were visualized by incubation with
10 lg/ml 40,6-diamidino-2-phenylindole (DAPI; Merck, Darmstadt,
Germany) and CS-E was visualized by immunofluorescence, sec-
tions were mounted with cover glasses in mowiol-488.
2.3.2. Binding to peri-cellular chondroitin sulfate E in vitro
Although CS-E in ovarian carcinomas is predominantly localized
in the cancer stroma and not (peri)cellularly, we used cell lines
which do or do not produce CS-E in vitro as a model for analyzing
the binding properties of the delivery system. Cell lines SKOV3
(ATCC, #HTB 77) and SKOV3-F7 (overexpressing CS-E [28]) showed
strong (peri)cellular CS-E expression while cell line HFF1 (ATCC,
#SCRC-1041) showed no CS-E expression (Supplementary data,
Fig. S1). Cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM)-glutamax (Gibco, ThermoFisher scientific, Waltham, MA,
USA) containing 10% fetal bovine serum (PAN Biotech, Aidenback,
Germany) (v/v) and 100 I.U./ml penicillin and 100 lg/ml strepto-
mycin (Amresco, Solon, OH, USA), at 37 C in a humidified incuba-
tor in a 5% CO2 atmosphere. When 80% confluency was reached,
cells were dissociated using 0.05% trypsin (w/v) in 0.53 mM EDTA
in Hank’s balanced salt solution (Corning Mediatech, Tweksbury,
MA, USA) and maintained as proliferating cultures. Cells were
tested for mycoplasma contamination every four months using a
MycoAlertTM mycoplasma detection kit (Lonza, Basel, Switzerland).
After thawing, cells remained in culture for a maximum of six
months.
Cells were cultured in 10-well glass slides in 75 ll medium to
P90% confluency. Next, cells were fixed with 4% paraformalde-
hyde (Sigma-Aldrich) in PBS (v/v) for 20 min, blocked with 2%
BSA in PBS (w/v) and subsequently incubated for 1 h with
0.1 mg/ml antibody-functionalized lyophilisomes or non-
functionalized lyophilisomes. Cells were incubated with 10 lg/ml
DAPI for nuclear staining and mounted in Mowiol-488.
2.3.3. Binding to immobilized chondroitin sulfate E
To evaluate the specificity of the antibody-functionalized
lyophilisomes for CS-E, the following glycosaminoglycans were
coated onto a 10-well glass slide (Thermo Fisher Scientific, Wal-
tham, USA) all at 0.1 mg/ml: CS-A (from bovine trachea, Sigma-
Aldrich), CS-B (dermatan sulfate, from porcine intestinal mucosa,
Celsus Laboratories Inc.), CS-C (from shark cartilage, Sigma-
Aldrich), CS-D (from shark cartilage, Seikagaku), CS-E (from squid
cartilage, Seikagaku), heparin (from porcine intestinal mucosa,
Sigma-Aldrich), and heparan sulfate (from bovine kidney, Sigma-
Aldrich). After blocking with 2% BSA in PBS (w/v), glass slides were
incubated for 1 h at room temperature with either antibody-
functionalized lyophilisomes or non-functionalized lyophilisomes
(0.1 mg/ml), or GD3G7 antibodies as control. Thereafter, glass
slides were rinsed in PBS and mounted in Mowiol-488 (Cal-
biochem, La Jolla, CA, USA). Lyophilisomes were visualized using
their FITC label.
Analyses were performed using a Leica DM6000B fluorescent
microscope. Image processing was performed using ImageJ 1.48v
(National Institutes of Health, USA). For visualization purposes,
brightness and contrast were adjusted similarly for all images
including the controls.
2.4. Visualization of chondroitin sulfate E
The expression of CS-E was visualized by immunofluorescence
or by applying the avidin-biotin complex method [29]. In brief,
slides were incubated with the GD3G7 antibody (1:5) after block-
ing, followed by a mouse anti-VSV antibody (clone P5D4, 1:10) and
either a goat anti-mouse IgG Alexa Fluor 488 (Life Technologies,
1:500) or biotinylated horse-anti-mouse IgG antibody (Vector Lab-
oratories Inc., CA, USA, 1:200) and ABC reagent (Vectastain ABC
anti-mouse-IgG kit, Vector Laboratories Inc.).
2.5. Evaluation of cytotoxic potential of antibody-functionalized
lyophilisomes
2.5.1. Cytotoxicity analysis in vitro
The cell eliminating potential of doxorubicin loaded, antibody-
functionalized lyophilisomes was investigated using a cell viability
assay. To mimic a CS-E rich extracellular matrix, 96-wells cell cul-
ture plates (Corning Costar, NY, USA) were coated overnight with
CS-E (0.1 mg/ml). The next day, non-immobilized CS-E was
removed by washing with PBS and wells were incubated with
either: (1) culture medium, (2) Caelyx (PEGylated liposomal dox-
orubicin, Janssen-Cilag B.V., Tilburg, the Netherlands), (3) free dox-
orubicin (Accord Healthcare, Utrecht, the Netherlands), (4) empty
non-functionalized lyophilisomes, (5) empty antibody-
functionalized lyophilisomes, (6) doxorubicin loaded non-
functionalized lyophilisomes and (7) doxorubicin loaded,
antibody-functionalized lyophilisomes, all preparations were
diluted in culture medium. Doxorubicin concentration was
20 lM and the amount of lyophilisomes with or without doxoru-
bicin were equal. After incubation for 1 h at 37 C, wells were
washed with culture medium. Subsequently, 5000 SKOV3-F7 cells
were seeded in 100 ll medium and cell viability was measured
after 5 days. Wells were washed with medium and 100 ll medium
containing 10% (v/v) Alamar blue reagents (ThermoFisher Scien-
tific) was added with an incubation time of 4 h at 37 C. Cell viabil-
ity was measured by fluorescence (excitation at 570 nm, emission
at 585 nm) using a Synergy BioTek 2 Plate reader (BioTek,
Winooski, VT, USA).
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2.5.2. In vitro doxorubicin release
To determine whether lyophilisomes can eliminate cells by
releasing doxorubicin, but without entering cells, an in vitro exper-
iment using 2 kDa cut-off membranes (Slide-A-LyzerMINI dialysis
units 2000 MWCO, Thermo Scientific) was conducted. Free doxoru-
bicin will pass the membrane, but doxorubicin in lyophilisomes or
liposomes will not. 5000 SKOV3-F7 cells were seeded in the upper
compartment of the membrane, while in the lower compartment
the following conditions were added: (1) culture medium, (2) 5
or 20 lM Caelyx (liposomal doxorubicin), (3) 5 or 20 lM free dox-
orubicin, (4) lyophilisomes, (5) 5 or 20 lM doxorubicin in lyophili-
somes, (6) PBS and (7) 5 lM doxorubicin in lyophilisomes in PBS.
The amount of doxorubicin loaded and empty lyophilisomes was
equal. After 48 h, 30 ll medium containing 30% (v/v) Alamar blue
was added to the cells, with an incubation time of 4 h at 37 C. Cell
viability was measured as described.
2.5.3. Visualization of cellular doxorubicin uptake
To visualize uptake of doxorubicin from lyophilisomes into cells
(nuclei), 5000 SKOV3F7 cells were cultured on a glass slide over-
night and subsequently incubated with either free doxorubicin,
Caelyx (liposomal doxorubicin) or lyophilisomes with or without
5 lM doxorubicin for 24 h. Finally, cells were washed once with
PBS and fixed with 4% paraformaldehyde (Sigma-Aldrich) in PBS
(v/v) for 10 min. Nuclei were stained with 10 lg/ml DAPI in PBS
(w/v) for 10 min and cells were mounted in Mowiol-488. Analyses
were performed using a Leica DM6000B fluorescent microscope.
2.6. Statistical analysis
Statistical analyses were tested by one-way analysis of variance
(ANOVA) with posthoc Bonferroni’s Multiple Comparison Test
using Graphpad Prism version 5.03 (Graphpad software, La Jolla,
CA, USA). All tests were two-sided and p-values <0.05 were consid-
ered significant. All experiments were performed at least three
times independently.
3. Results
3.1. Generation and evaluation of antibody-functionalized
lyophilisomes
Because random conjugation of single chain antibodies to albu-
min lyophilisomes using classical 1-ethyl-3-(3-dimethylaminopro
pyl)carbodiimide/N-Hydroxysuccinimide (EDC/NHS) chemistry
carries a risk of modifying amino acids that are crucially involved
in antigen binding, we chose to develop a method of controlled
and site-specific conjugation using sortagging (Fig. 1). GD3G7 anti-
bodies harboring the LPETG sortase consensus motif (molecular
weight of 28.5 kDa) could be readily produced and purified and
were labeled with PEG-DBCO (Fig. 2A). The product was analyzed
by a click reaction between DBCO and azido-cyanine 7.5, and in
line with expectation, was only seen for GD3G7-PEG-DBCO as
was demonstrated by SDS-PAGE analysis (lane 3 in Fig. 2A; note
that the molecular weight of the GD3G7-DBCO-N3-cyanine 7.5 is
slightly lower than the unreacted GD3G7-LPETG-His-VSV in lane
2, due to loss of the G-His-VSV tag during the sortase reaction).
The conjugation of amino-PEG4-azide to the surface of lyophili-
somes was evaluated using flow cytometry. After incubation with
DBCO-IR dye 680RD, which only binds azide modified lyophili-
somes, the median fluorescent intensity of azide-conjugated
lyophilisomes was 631 (95% confidence interval [CI]: 578–684)
compared to 26 (95% CI: 21–30) for non-conjugated lyophilisomes
(p < 0.001) (Fig. 2B). Conjugation was further evaluated by using
peroxidase-conjugated Protein A, which binds to single chain
antibodies of the VH3 class, as is antibody GD3G7. High levels
of Protein A bound to antibody-functionalized lyophilisomes
compared to non-functionalized lyophilisomes [0.71 (95% CI:
0.53–0.89) vs 0.19 (95% CI: 0.11–0.27), p < 0.001] (Fig. 2C).
Loading of lyophilisomes with doxorubicin resulted in a mean
entrapment efficiency of 28% (95% CI: 18–38%), which corresponds
with a mean drug loading of 0.35 mg doxorubicin/mg lyophili-
somes (95% CI: 0.23–0.48).
3.2. Specificity of antibody-functionalized lyophilisomes
Targeting properties of antibody-functionalized lyophilisomes
were analyzed in patient derived ovarian cancer tissues
(Fig. 3A and B). Cryosections of high grade serous ovarian carcino-
mas were incubated with antibody-functionalized lyophilisomes
and non-functionalized lyophilisomes. An abundancy of
antibody-functionalized lyophilisomes associated with the cancer
stroma (containing CS-E), whereas almost no binding to ovarian
cancer epithelial cells was observed. Non-functionalized lyophili-
somes showed background reactivity with both the ovarian cancer
stroma and epithelial cells (Fig. 3A). Specificity of binding was
assayed by pretreatment of ovarian cancer sections with the chon-
droitin sulfate degrading enzyme chondroitinase-AC. Enzymatic
treatment abolished the reactivity of antibody-functionalized
lyophilisomes with the ovarian cancer stroma (Fig. 3A).
The specificity of antibody-functionalized lyophilisomes was
further analyzed in vitro using two human ovarian cancer cell lines
producing CS-E (SKOV3 and SKOV3F7) and a cell line not producing
CS-E (HFF1 cells, human foreskin fibroblasts) (Fig. 3B). The
antibody-functionalized lyophilisomes showed strong reactivity
with the CS-E producing cell lines (SKOV3 and SKOV3F7) compared
to the CS-E-negative cell line HFF1. The non-functionalized
lyophilisomes showed limited reactivity with any type of cell line.
Finally, the specificity of the antibody-functionalized lyophili-
somes for various glycosaminoglycans was determined.
Antibody-functionalized lyophilisomes showed strong reactivity
with the highly sulfated CS-E subtype (Fig. 3C), while only back-
ground signal was observed with other immobilized glycosamino-
glycans including CS-A, CS-B (also known as dermatan sulfate), CS-
C, CS-D, heparan sulfate and heparin. The non-functionalized
lyophilisomes showed no significant reactivity with any type of
glycosaminoglycan (Supplementary data, Fig. S2).
3.3. Cytotoxic potential of drug loaded, antibody-functionalized,
lyophilisomes in vitro
A CS-E rich environment was created to assess the effect of dox-
orubicin loaded antibody-functionalized lyophilisomes on ovarian
cancer cells. As shown in Fig. 4A, viability of cells cultured in CS-
E coated wells that were pre-incubated with doxorubicin loaded
antibody-functionalized lyophilisomes was decreased to 30%
(95% CI: 22–39%), and was significantly lower compared to the cell
viability after pre-incubation with doxorubicin loaded non-
functionalized lyophilisomes, free doxorubicin, and Caelyx (liposo-
mal doxorubicin) of 77% (95% CI: 65–89%), 70% (95% CI: 65–75%),
and 103% (95% CI:97–109%), respectively (p < 0.001). Empty
lyophilisomal control conditions (functionalized or non-
functionalized) did not affect cell viability.
3.4. Mode of doxorubicin release and nuclear localization
To study whether cell death occurs by extracellular release of
doxorubicin from lyophilisomes or by cellular uptake of doxoru-
bicin loaded lyophilisomes, an in vitro study using 2 kDa cut-off
membranes was performed. 2 kDa membranes allow free doxoru-
bicin (544 Da) to pass, but not larger components such as
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lyophilisomes-associated doxorubicin, Caelyx (liposomal doxoru-
bicin), cells, and enzymes. Free doxorubicin and doxorubicin
loaded lyophilisomes in culture medium containing 10% FBS
decreased cell viability in the upper compartment to 46.7% (95%
CI: 39.4–54.0%, p < 0.001) and 39.5% (95% CI: 25.9–53.1%,
p < 0.001), respectively (Fig. 4B). In contrast, equal doses of Caelyx
and empty lyophilisomes did not significantly affect cell viability,
97.9% (95% CI: 83.3–112.4%) and 93.9% (95% CI: 74.6–113.2%),
respectively. Moreover, a lower dose of 5 lM of free doxorubicin
and doxorubicin in lyophilisomes significantly affected cell viabil-
ity, whereas the same concentration of Caelyx did not; interest-
ingly, doxorubicin loaded lyophilisomes in PBS did not
significantly affect cell viability (Supplementary data, Fig. S3).
After incubation of cells with lyophilisomes loaded with dox-
orubicin, the drug localized to the nuclei, the site of action (Fig. 4C).
This was also observed with free doxorubicin, but not with Caelyx
under the same conditions (24 h of incubation).
3.5. Generality of CS-E expression in the stroma of solid cancers
In order to explore the stromal CS-E expression associated with
various solid cancers other than ovarian, we immunohistochemi-
cally analyzed five samples of lung, cervical, breast, renal cell,
endometrial, and colon cancer for the expression of CS-E. In the
vast majority of each cancer type, stromal overexpression of CS-E
was observed (Fig. 5).
4. Discussion
In the current study, we have evaluated the feasibility of a novel
concept of therapeutic tumor targeting based on an ECM-targeting
drug delivery system. Largely neglected, the cancer ECM provides
potential targets for therapy and may have advantages over target-
ing cancer cells. Due to intra-tumoral heterogeneity, targeted ther-
apies against cancer cell specific targets may act only on a
subpopulation of cancer cells whilst other subpopulations not
expressing the target, and cancer-associated stromal cells (i.e.
fibroblasts and endothelial cells), are left unaffected [21]. Cancer-
associated stromal cells have been identified as significant contrib-
utors to cancer growth and dissemination, and the additional elim-
ination of these cells may benefit clinical outcome [30,31].
Furthermore, expression of cancer cell specific targets may change
over time resulting in resistance to the applied targeted therapy
[13]. Targeting anti-cancer drugs to the more stable ECM may be
helpful to overcome these hurdles.
The potency of ECM-targeting therapies is supported by recent
studies which have demonstrated that delivering anti-cancer drugs
to the tumor stroma can successfully eliminate tumor cells and
their micro-environment in vivo [23,24]. However, the approaches
that were used in these studies were of limited translational value
because these were not specific for the cancer stroma. Because the
antibody-functionalized lyophilisomes in our study target a unique
cancer-specific stromal antigen, this may result in a more specific
Fig. 2. Evaluation of antibody-functionalized lyophilisomes. (A) SDS-PAGE evaluation of sortase mediated ligation of amino-PEG4-DBCO to the GD3G7 antibody harboring a
LPETG motif, using azido-cyanine 7.5 labeling. Coomassie brilliant blue staining and visualization in the 800 nm channel of GD3G7-PEG4-DBCO and unmodified GD3G7
antibodies after azido-cyanine 7.5 labeling; (B) Median fluorescent intensity (MFI) of azide-conjugated lyophilisomes and non-conjugated lyophilisomes after DBCO-IR dye
680RD labeling assessed by flow cytometry; (C) Absorbance of DBCO-modified GD3G7 antibodies conjugated to azide-conjugated lyophilisomes detected by the binding of
peroxidase-conjugated protein A. Unmodified GD3G7 antibodies and non-conjugated lyophilisomes were included as controls; Bars represent mean ± standard deviation
(n = 3). ⁄⁄⁄ indicates a statistical significant difference with p < 0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
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Fig. 3. Specificity of antibody-functionalized lyophilisomes for highly sulfated chondroitin sulfate E (CS-E). (A) Effect of chondroitin sulfate degrading enzymes on targeting
properties of antibody-functionalized lyophilisomes and non-functionalized lyophilisomes. Ovarian cancer cryosections were pre-incubated with either chondroitinase-AC
that digests CS (ChAC+), or buffer without enzyme (ChAC). Sections were stained with GD3G7 antibodies (visualized in red by Alexa-594) to indicate presence of CS-E chains
in the cancer stroma. The general histology of the ovarian carcinoma cryosection is visualized by hematoxylin and eosin (H&E) staining and show epithelial cancer cells
(marked with asterisk) surrounded by cancer-associated stroma. (B) Reactivity of antibody-functionalized lyophilisomes and non-functionalized lyophilisomes with CS-E
producing cell lines (SKOV3-F7, SKOV3) and a non CS-E producing cell line (HFF1); (C) Reactivity of antibody-functionalized lyophilisomes and non-functionalized
lyophilisomes with immobilized glycosaminoglycans CS-E and heparin, the reactivity with GD3G7 antibodies was used as control; Abbreviations: Ab, antibody. Scale bar
represents 100 lm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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tumor targeting with concomitant less exposure to healthy
surrounding tissues [23,24].
Here we report that antibody-functionalized lyophilisomes,
generated by a stable and specific bioorthogonal click reaction
between GD3G7-PEG4-DBCO and azido-functionalized lyophili-
somes, have specific binding properties for the ovarian cancer
stroma rich in CS-E motifs. In addition and focusing on targeting
characteristics, ovarian cancer cells in a CS-E rich micro-
environment were efficiently eliminated by antibody-
functionalized lyophilisomes loaded with doxorubicin, in contrast
to non-functionalized lyophilisomes and Caelyx (liposomal dox-
orubicin), the latter being a commonly used second line
chemotherapeutic for the treatment of ovarian cancer. These
results indicate the potential of the ECM-targeting drug delivery
system as a novel class of targeted therapy for the treatment of
ovarian cancer.
To achieve specific stroma-targeting of the drug delivery sys-
tem, we applied a two-step approach comprising sortase mediated
ligation and bioorthogonal click chemistry. First, we equipped sin-
gle chain GD3G7 antibodies with a click chemistry handle using
the recently published sortagging approach [32]. Sortase A, a
transpeptidase from Staphylococcus aureus, recognizes a LPXTG
motif and catalyses cleavage between threonine and glycine resi-
dues forming an intermediate complex [33]. The complex is then
Fig. 4. Cell viability and doxorubicin release in vitro. (A) A chondroitin sulfate E (CS-E) rich environment was pretreated with either doxorubicin loaded lyophilisomes with/
without antibody functionalization, free doxorubicin or Caelyx (liposomal doxorubicin), all preparations containing 20 lM doxorubicin. After washings, ovarian tumor cells
(SKOV3F7) were cultured and viability was assayed. Antibody-functionalized lyophilisomes with doxorubicin were most effective in eliminating ovarian cancer cells. (B)
Viability of SKOV3F7 cells cultured on a 2 kDa dialysis membrane separating them from a lower compartment containing various conditions. Doxorubicin loaded
lyophilisomes and free doxorubicin were equally effective, whereas Caelyx (liposomal doxorubicin) did not affect the cell viability. (C) Nuclear localization of lyophilisomal
derived doxorubicin in vitro. SKOV3F7 cells were incubated for 24 h either with free doxorubicin, Caelyx (liposomal doxorubicin), empty lyophilisomes (depicted in green) or
doxorubicin loaded lyophilisomes (depicted in red). Nuclei were stained blue with DAPI. Free doxorubicin and released doxorubicin from lyophilisomes localized to the nuclei
(colored red). ⁄⁄⁄ indicates a statistical significant difference with non-asteriks marked conditions with p < 0.001. Bars represent mean ± standard deviation (n = 3). Scale bar
represents 100 lm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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resolved by a nucleophilic attack of the N-terminal protein thus
forming a covalent bond [34]. Recently, it has been demonstrated
that amine groups of other compound (e.g. amino-PEG) can be sub-
strate for the LPETG-sortase intermediate thus offering a versatile
toolbox for sortase A catalyzed ligations in protein engineering
[35]. By positioning the LPETG sequence upstream of purification
tags, these tags can be replaced with handles for click chemistry,
while allowing convenient and rapid purification of the reaction
product from unreacted proteins and by-products of the reaction.
Using this system we generated GD3G7-PEG4-DBCO with high pur-
ity. Of note, because the click handle is positioned at the extreme
carboxyterminal end, there is a minimal risk of affecting antibody
affinity, unlike the widely used approach of EDC/NHS-mediated
conjugation.
Lyophilisomes were used here as biocapsules for doxorubicin,
and represent an attractive class of drug delivery systems for
ECM-targeting since they can be prepared in a wide range of size
(100 nm–10 lm), thereby being eligible for systemic as well as
intraperitoneal administration [11]. Ovarian cancer has a unique
tumor biology and metastatic spread pattern since it is usually
confined to the peritoneal cavity. Standard treatment regimes
include debulking surgery and systemic chemotherapy. As these
patients especially suffer from extensive abdominal metastases,
delivering adjuvant chemotherapeutics into the peritoneal cavity
in addition to systemically administered chemotherapy, has been
shown to significantly improve survival rates of ovarian cancer
patients and is currently the standard of care for a selected group
of patients [36–39]. Lyophilisomes can be prepared with a diame-
ter as small as 100–200 nm allowing them to extravasate from
leaky intratumoral vessels and accumulate in the cancer intersti-
tium (enhanced permeability and retention effect) [40,41]. By sub-
sequently binding to CS-E chains located in the stroma adjacent to
intratumoral vessels, longer retention of nanoparticles in the can-
cer tissue and increased treatment efficacy may be achieved. On
the other hand, it has been proposed that micro-metastases
(61 mm) at the peritoneum have no vasculature and consequently
will not be reached by systemic therapy [42]. For an (adjuvant)
intraperitoneal application, the use of micro-sized particles over
nano-sized particles may be of benefit since uptake of microsized
particles from the abdominal cavity into the circulation is
restricted, thus elongating intraperitoneal half life and treatment
efficacy [43]. The use of a targeted drug delivery system for the
intraperitoneal treatment of ovarian cancer may be of major inter-
est since the beneficial effect of intraperitoneally administered
chemotherapeutics is limited by substantial (local) toxicity [38].
Intense stromal CS-E expression has been associated with vari-
ous ovarian cancer subtypes including low grade and high grade
serous, clear cell, and low grade and endometrioid cancer [20]. In
this study we showed that CS-E was highly upregulated in the
stroma of a variety of solid tumors including breast cancer,
endometrioid cancer, cervical cancer, lung cancer, colon cancer,
and renal cell cancer. Accordingly, delivery systems targeting CS-
E may be applicable to a large and diverse group of cancers.
Release of drugs from stroma-targeting lyophilisomes is essen-
tial to eliminate cells. We demonstrated that doxorubicin loaded
lyophilisomes in fetal bovine serum enriched culture medium
release a substantial part of their drug resulting in nuclear localiza-
tion of the drug (the site of action) and ovarian cancer cell death, in
contrast to (Caelyx) liposomal doxorubicin that did not affect cell
viability. This release cannot be explained by simple diffusion as
the release in a neutral buffer (PBS) was minimal and did not result
in cell death. Albumin represents an important transport protein
and is known for its non-covalent reversible ligand-binding capac-
ity. Moreover, it has several binding sites for hydrophobic compo-
nents which may explain the affinity of albumin for doxorubicin,
maintaining the drug within lyophilisomes [10] and which may
contribute to the high drug loading capacity compared to Caelyx
(0.35 mg doxorubicin/mg lyophilisomes vs 0.125 mg doxorubicin/
mg liposomes) [44]. We hypothesize that hydrophobic compo-
nents (e.g. fatty acids) or free albumin in serum-enriched medium
may compete with the albumin-doxorubicin binding and lead to
drug release. In addition, proteolytic enzymes in the cancer stroma
may contribute to the degradation of the albumin lyophilisomes
thus enabling release of its payload [45]. In order to enhance drug
release, antibody-functionalized lyophilisomes hold potential for
additional functionalization, e.g. by the incorporation of substrates
for proteolytic enzymes upregulated in the ovarian cancer ECM,
into the albumin wall.
Fig. 5. Stromal chondroitin sulfate E (CS-E) expression (in red) in various solid cancers including lung cancer, cervical cancer, breast cancer, renal cell cancer, endometrial
cancer, and colon cancer. Scale bar represents 100 lm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
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5. Conclusion
In this study, we constructed and evaluated a drug delivery sys-
tem targeting the cancer-associated stroma, based on albumin
lyophilisomes loaded with doxorubicin and functionalized with
antibodies to highly sulfated chondroitin sulfates. The delivery sys-
tem may contribute to a novel class of therapy, based on address-
ing specific components in the extracellular matrix of tumors.
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